Sulphathiazole Sodium Pentahydrate

Degradation Kinetics and Sterile Filtration Parameters in Injectable Sulfathiazole Sodium Solutions

Formulation of parenteral veterinary products utilizing sulphathiazole sodium pentahydrate begins with dissolution of the crystalline salt in Water for Injection (WFI) at concentrations equivalent to 100–200 mg/mL anhydrous sulfathiazole base, a range that mandates a gravimetric correction factor of approximately 1.35 to compensate for the 27–30% mass contributed by the five water molecules of crystallization. The solution pH is raised to 8.5–9.5 with sodium hydroxide to maintain complete solubility during subsequent heat exposure; however, at pH values exceeding 10.0, the hydrolytic ring-opening of the thiazole moiety accelerates, generating sulfanilamide-related impurities that must be controlled below 0.5% according to Ph. Eur. monograph 10.0, 0253. Terminal moist-heat sterilization is typically conducted in a rotary autoclave with a validated F₀ ≥ 8 ( 121°C for 15 minutes ), during which microcalorimetric studies per ASTM E968-02 reveal measurable lattice water redistribution within the sealed primary container. If the headspace relative humidity exceeds 60% at the end of the cool-down phase, condensate triggers localized precipitation of the free sulfathiazole acid, visually detectable as opalescent particles and quantifiable by USP <788> light obscuration particle counts with an acceptance limit of ≤ 25 particles/mL at ≥ 10 µm. Sterile filtration is executed using double-layer 0.22 µm polyethersulfone membrane cartridges (e.g., Sartorius Sartopore 2) maintained under a nitrogen blanket at a differential pressure not exceeding 2.0 bar, as higher ΔP induces shear-mediated nucleation of insoluble dimers that reduce flow rate by 40–60% post-filtration. Process validation documentation references FDA 21 CFR 211.113 (sterilization) and VICH GL 18 (residual solvents in veterinary products), with bioburden prior to filtration consistently reported below 10 CFU/100 mL. Finished product configurations include aqueous injectables in amber Type II glass vials of 100 mL and 250 mL as well as lyophilized powders for reconstitution, the latter processed on a Telstar LyoBeta industrial freeze-dryer with shelf temperature ramping from −40°C to +30°C over 36 hours to yield a cake moisture content below 1.5%.

What Practical Solubility Limits Oral Drench and Drinking Water Medication?

When sulphathiazole sodium pentahydrate is incorporated into water-soluble powders for mass medication via drinking lines, the saturation behaviour in hard water represents a non-negligible variability factor. Potentiometric titration following ISO 7887:2011 demonstrates that the apparent solubility in deionized water exceeds 500 mg/mL at 25°C, yet this drops sufficiently when bicarbonate hardness surpasses 200 mg/L CaCO₃ to produce a turbidity rise above 10 NTU, a consequence of transient calcium-sulfathiazole complex formation that can foul nipple drinker systems. To ensure target dosing of 1.0–2.0 g active substance per litre of final drinking water, the dry concentrate is formulated to contain 60–75% w/w of the pentahydrate salt (anhydrous basis content 73–92% after weight correction) along with dextrose monohydrate as a dispersing carrier and a 0.5–1.5% w/w addition of anhydrous sodium carbonate to buffer the reconstitution pH between 8.0 and 9.0. Powder blending is carried out in 2000 L V-shell tumble blenders operated at 12 rpm for 45–60 minutes, with blend uniformity assessed by inline near-infrared spectroscopy per ASTM E1655 at six predefined sampling points; acceptance requires a relative standard deviation below 5.0%. The mixed powder undergoes forced-air convection drying at an inlet temperature no higher than 45°C, where the outlet air dewpoint must be held below −5°C as continuously monitored by a chilled mirror hygrometer—any excursion above this threshold removes lattice water and shifts the assay by more than 3% relative to label claim. The final heat-sealed sachets utilize a 100 µm aluminum-polyethylene laminate with a water vapour transmission rate below 0.5 g/m²/24h (ASTM F1249-20). Conformity to the Chinese Veterinary Pharmacopoeia 2020 monograph for Sulfathiazole Sodium Soluble Powder is demonstrated through content uniformity testing per CVP Appendix 0103 (acceptance value ≤ 15.0) and loss-on-drying determination at 105°C for 4 hours. Terminal dosage forms comprise water-soluble sachets of 100 g and 500 g and oral drench suspensions packaged in 1 L and 5 L jerrycans, labelled with sulfathiazole base concentrations of 20% or 33.3% w/v.

Premix Pelleting Survival Rates When Die Temperature Exceeds 70°C

Incorporation of sulphathiazole sodium pentahydrate into medicated feed premix and pelleted feed relies on uniform dispersion into milled corn cob or wheat middlings, with a target active substance concentration of 50–220 mg/kg complete feed (equivalent to 100–220 g anhydrous sulfathiazole per kilogram of premix). The critical process conflict arises during ring-die pellet mill operation when preconditioning steam raises mash temperature above 65°C. At die hole temperatures of 70–85°C, partial dehydration of the pentahydrate lattice liberates crystallization water that reacts with the acid-sensitive sulfonamide nucleus, forming hydrogen sulfide by-products detectable by gas sensor arrays at concentrations above 2 ppm. Recovered active compound in finished pellets stored for 72 hours at 25°C/ 60% RH declines to 82–88% of initial assay, while unprocessed mash retains ≥97%. Compensatory overage additions of 10–12% are applied when pelleting cannot be performed below the critical threshold, though this approach introduces batch-to-batch content variability of up to 8% RSD. A validated mitigation strategy employs a cold-pelleting configuration using a preconditioner with steam at 0.5 bar and immediate post-pellet forced-air cooling in a counterflow cooler (e.g., Geelen Counterflow 6000), which maintains mash temperature ≤ 55°C and pellet exit temperature ≤ 42°C. The finished premix must comply with the homogeneity requirements of the GMP+ Feed Safety Assurance scheme, module BA1, where a minimum of 10 random sampling points must yield a sulfathiazole assay coefficient of variation below 7.0% when analyzed by HPLC per FDA 21 CFR 558.630 historical performance criteria. Terminal products are packaged in 25 kg three-ply paper bags with inner polyethylene liner and includeType A medicated article premixes and pelleted feeds for poultry and swine where regional marketing authorizations permit.

Producing trimethoprim-sulfathiazole combination premixes requires precise stoichiometric control because the synergistic 5:1 ratio (sulfathiazole:trimethoprim) that drives the microbiological potency is susceptible to segregation during material handling. The physical mixture combines sulphathiazole sodium pentahydrate with trimethoprim (micronized, d₉₀ ≤ 15 µm) at label strengths typically set at 250 g sulfathiazole and 50 g trimethoprim per kilogram. Bulk density differentials—approximately 0.65 g/cm³ for the pentahydrate against 0.35 g/cm³ for trimethoprim—necessitate the use of bin blenders equipped with intensifier bars (e.g., Matcon IBC R100) operated at 3000 rpm tip speed for 3–5 minutes after a geometric dilution step. Direct compression of the resultant powder into oral boluses is avoided unless the moisture content of the entire blend is first reduced to ≤ 2.5% w/w via vacuum drying at 10 mbar and 40°C, because residual water catalyzes a slow Maillard-like interaction between the primary arylamine of trimethoprim and the sulfonamide nitrogen, evidenced by a 4–6% drop in potency over 12 months at 30°C/ 65% RH. Instead, the granulated form is preferred: wet granulation using an isopropanol-water azeotrope (95:5 v/v) in a high-shear mixer-granulator (e.g., Diosna P 1/6) followed by fluid-bed drying at 50°C until LOD reaches 1.5–2.0% maintains both active substances within 95–105% of label claim through the assigned shelf life. The combination product must satisfy VICH GL 36 stability requirements for fixed-dose combination veterinary medicinal products, with a forced degradation study demonstrating chromatographic separation of all potential interaction peaks (resolution ≥ 2.0 per Ph. Eur. 10.0). Finished forms encompass oral powders in sachets and effervescent tablets, as well as injectable co-formulations when sodium sulfathiazole is paired with trimethoprim lactate at low-volume doses for cattle.

Immersion bath protocols for freshwater aquaculture species infected with Aeromonas hydrophila or Edwardsiella ictaluri utilize sulphathiazole sodium pentahydrate at concentrations of 10–20 mg active ingredient per litre of pond or tank water. The pentahydrate is pre-dissolved in a 100 L mixing vessel using a Venturi-type eductor to create a stock solution containing 5–10% w/v, which is then distributed across the rearing unit to achieve the target therapeutic bath for a 6–8 hour static immersion. Unlike in-feed administration, the immersion route demands that the ionic composition of the source water be characterized in advance: carbonate hardness above 300 mg/L CaCO₃ reduces the effective dissolved concentration by approximately 15% through adsorption onto suspended carbonate particulates. The protocol compliance framework references the FAO Technical Guidelines on Aquaculture Certification and section 6.3 of the OIE Aquatic Animal Health Code for responsible use of antimicrobials in aquaculture; residue surveillance programs then apply a withdrawal period of 21 days at water temperatures above 18°C, verified by LC-MS/MS quantification of sulfathiazole in edible tissue with a maximum residue limit set at 100 µg/kg by Codex Alimentarius. Processing of the bath product itself is limited to dry blending and vacuum sealing in moisture-barrier sachets of 500 g and 1 kg, with a certificate of analysis confirming crystal water content by Karl Fischer titration (USP <921>, Method Ia) within 26.5–30.0% w/w prior to release.

Intrauterine foaming tablets for bovine metritis are designed around the effervescent reaction of sulphathiazole sodium pentahydrate with a compacted citric acid–sodium bicarbonate couple, delivering local antibacterial concentrations directly to the endometrium. Each tablet is formulated to contain 5.0 g of the pentahydrate salt (equivalent to 3.6 g anhydrous sulfathiazole), together with citric acid monohydrate 2.5 g, sodium bicarbonate 3.2 g, and a polyethylene glycol 6000 binder at 2.0% w/w to cap the reaction kinetics. Direct compression on a rotary tablet press (e.g., Fette 3090i) using 25 mm flat-faced bevel-edge punches generates a tablet hardness of 40–60 N crucial to preventing premature chipping during automatic dispensing, yet friability must remain below 1.0% per USP <1216>. Disintegration testing in 500 mL simulated uterine fluid at 39°C per USP <701> yields a finely dispersed suspension within 3–5 minutes, a specification that becomes unattainable if the lubricant magnesium stearate exceeds 0.8% w/w because it forms a hydrophobic film on the effervescent granules. The dosage form must be packaged in induction-sealed aluminium strips with individual desiccant sachets, as the pentahydrate under high tropical humidity (> 75% RH at 30°C) initiates a premature acid-base reaction, raising strip dewpoint and reducing tablet efficacy by over 30% within 6 weeks. Compliance with the manufacturing requirements of EU Regulation 2019/6 Annex 11 (veterinary medicinal products) is verified through in-process hardness and disintegration monitoring on a statistical sampling plan of 20 tablets per 15-minute compression interval. Terminal product configurations also include intrauterine pessaries and non-effervescent suspensions, the latter using an oil-based vehicle to avoid water-exacerbated degradation.